Log in to your account:
Viking Therapeutics (VKTX) Gains Post-Market Following Gilead's Study Failure
February 11, 2019 4:44 PM
Viking Therapeutics ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Gilead Sciences (GILD) Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to NASH Doesn't Meet Primary Endpoint
February 11, 2019 4:32 PM